Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors.
Azer-cel
UPDATE
“We are delighted to be working with NIT on the potential to enhance azer-cel activity as part of this research collaboration.” - Leslie Chong, CEO
onCARlytics (CF33-CD19) is a novel and effective combination immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells promoting CD19 CAR T cell anti-tumour responses against solid tumours.
Our lead candidate is a chimeric vaccinia (pox) virus known as CF33, developed by Professor Yuman Fong, at the prestigious City of Hope Comprehensive Cancer Center in Los Angeles, California.
HER-Vaxx is a B-cell immuno-therapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
PD1-Vaxx is a B-cell immuno-therapy which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies
Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours.
Read our latest Health Care: Biotechnology Equity Research and Company Notes.
CEO UPDATE : After yet another busy few months for Imugene in which we’ve taken several pivotal steps forward, I’m thrilled to bring you the latest edition of our shareholder newsletter.
Subscribe for all Company Updates
Sign up with your email address to receive news and updates.